146 related articles for article (PubMed ID: 25569186)
1. Identification of the minimum peptide from mouse myostatin prodomain for human myostatin inhibition.
Takayama K; Noguchi Y; Aoki S; Takayama S; Yoshida M; Asari T; Yakushiji F; Nishimatsu S; Ohsawa Y; Itoh F; Negishi Y; Sunada Y; Hayashi Y
J Med Chem; 2015 Feb; 58(3):1544-9. PubMed ID: 25569186
[TBL] [Abstract][Full Text] [Related]
2. Effect of N-Terminal Acylation on the Activity of Myostatin Inhibitory Peptides.
Takayama K; Nakamura A; Rentier C; Mino Y; Asari T; Saga Y; Taguchi A; Yakushiji F; Hayashi Y
ChemMedChem; 2016 Apr; 11(8):845-9. PubMed ID: 26954624
[TBL] [Abstract][Full Text] [Related]
3. Discovery of a follistatin-derived myostatin inhibitory peptide.
Saitoh M; Takayama K; Hitachi K; Taguchi A; Taniguchi A; Tsuchida K; Hayashi Y
Bioorg Med Chem Lett; 2020 Feb; 30(3):126892. PubMed ID: 31874826
[TBL] [Abstract][Full Text] [Related]
4. Transgenic expression of a myostatin inhibitor derived from follistatin increases skeletal muscle mass and ameliorates dystrophic pathology in mdx mice.
Nakatani M; Takehara Y; Sugino H; Matsumoto M; Hashimoto O; Hasegawa Y; Murakami T; Uezumi A; Takeda S; Noji S; Sunada Y; Tsuchida K
FASEB J; 2008 Feb; 22(2):477-87. PubMed ID: 17893249
[TBL] [Abstract][Full Text] [Related]
5. Proposal for the binding mode of the 23-mer inhibitory peptide to myostatin.
Asari T; Ikeyama H; Taguchi A; Taniguchi A; Hayashi Y; Takayama K
Bioorg Med Chem; 2021 Jun; 40():116181. PubMed ID: 33957441
[TBL] [Abstract][Full Text] [Related]
6. The Inhibitory Core of the Myostatin Prodomain: Its Interaction with Both Type I and II Membrane Receptors, and Potential to Treat Muscle Atrophy.
Ohsawa Y; Takayama K; Nishimatsu S; Okada T; Fujino M; Fukai Y; Murakami T; Hagiwara H; Itoh F; Tsuchida K; Hayashi Y; Sunada Y
PLoS One; 2015; 10(7):e0133713. PubMed ID: 26226340
[TBL] [Abstract][Full Text] [Related]
7. Strategic structure-activity relationship study on a follistatin-derived myostatin inhibitory peptide.
Saitoh M; Takayama K; Roppongi Y; Shimada T; Taguchi A; Taniguchi A; Hayashi Y
Bioorg Med Chem Lett; 2021 Aug; 46():128163. PubMed ID: 34087433
[TBL] [Abstract][Full Text] [Related]
8. Overexpression of Latent TGFβ Binding Protein 4 in Muscle Ameliorates Muscular Dystrophy through Myostatin and TGFβ.
Lamar KM; Bogdanovich S; Gardner BB; Gao QQ; Miller T; Earley JU; Hadhazy M; Vo AH; Wren L; Molkentin JD; McNally EM
PLoS Genet; 2016 May; 12(5):e1006019. PubMed ID: 27148972
[TBL] [Abstract][Full Text] [Related]
9. Myostatin inhibition by a follistatin-derived peptide ameliorates the pathophysiology of muscular dystrophy model mice.
Tsuchida K
Acta Myol; 2008 Jul; 27(1):14-8. PubMed ID: 19108572
[TBL] [Abstract][Full Text] [Related]
10. Muscle-bone interactions in dystrophin-deficient and myostatin-deficient mice.
Montgomery E; Pennington C; Isales CM; Hamrick MW
Anat Rec A Discov Mol Cell Evol Biol; 2005 Sep; 286(1):814-22. PubMed ID: 16078270
[TBL] [Abstract][Full Text] [Related]
11. Myostatin/activin blocking combined with exercise reconditions skeletal muscle expression profile of mdx mice.
Kainulainen H; Papaioannou KG; Silvennoinen M; Autio R; Saarela J; Oliveira BM; Nyqvist M; Pasternack A; 't Hoen PA; Kujala UM; Ritvos O; Hulmi JJ
Mol Cell Endocrinol; 2015 Jan; 399():131-42. PubMed ID: 25304272
[TBL] [Abstract][Full Text] [Related]
12. The function of Myostatin and strategies of Myostatin blockade-new hope for therapies aimed at promoting growth of skeletal muscle.
Patel K; Amthor H
Neuromuscul Disord; 2005 Feb; 15(2):117-26. PubMed ID: 15694133
[TBL] [Abstract][Full Text] [Related]
13. Design and synthesis of potent myostatin inhibitory cyclic peptides.
Rentier C; Takayama K; Saitoh M; Nakamura A; Ikeyama H; Taguchi A; Taniguchi A; Hayashi Y
Bioorg Med Chem; 2019 Apr; 27(7):1437-1443. PubMed ID: 30777663
[TBL] [Abstract][Full Text] [Related]
14. Peptide-2 from mouse myostatin precursor protein alleviates muscle wasting in cancer-associated cachexia.
Ojima C; Noguchi Y; Miyamoto T; Saito Y; Orihashi H; Yoshimatsu Y; Watabe T; Takayama K; Hayashi Y; Itoh F
Cancer Sci; 2020 Aug; 111(8):2954-2964. PubMed ID: 32519375
[TBL] [Abstract][Full Text] [Related]
15. Identification of decorin derived peptides with a zinc dependent anti-myostatin activity.
Guiraud S; van Wittenberghe L; Georger C; Scherman D; Kichler A
Neuromuscul Disord; 2012 Dec; 22(12):1057-68. PubMed ID: 22854012
[TBL] [Abstract][Full Text] [Related]
16. Marked reduction of focal adhesion kinase, serum response factor and myocyte enhancer factor 2C, but increase in RhoA and myostatin in the hindlimb dy mouse muscles.
Sakuma K; Nakao R; Inashima S; Hirata M; Kubo T; Yasuhara M
Acta Neuropathol; 2004 Sep; 108(3):241-9. PubMed ID: 15221330
[TBL] [Abstract][Full Text] [Related]
17. Interference with myostatin/ActRIIB signaling as a therapeutic strategy for Duchenne muscular dystrophy.
Amthor H; Hoogaars WM
Curr Gene Ther; 2012 Jun; 12(3):245-59. PubMed ID: 22554312
[TBL] [Abstract][Full Text] [Related]
18. Functional improvement of dystrophic muscle by myostatin blockade.
Bogdanovich S; Krag TO; Barton ER; Morris LD; Whittemore LA; Ahima RS; Khurana TS
Nature; 2002 Nov; 420(6914):418-21. PubMed ID: 12459784
[TBL] [Abstract][Full Text] [Related]
19. Acute inhibition of myostatin-family proteins preserves skeletal muscle in mouse models of cancer cachexia.
Benny Klimek ME; Aydogdu T; Link MJ; Pons M; Koniaris LG; Zimmers TA
Biochem Biophys Res Commun; 2010 Jan; 391(3):1548-54. PubMed ID: 20036643
[TBL] [Abstract][Full Text] [Related]
20. Loss of myostatin attenuates severity of muscular dystrophy in mdx mice.
Wagner KR; McPherron AC; Winik N; Lee SJ
Ann Neurol; 2002 Dec; 52(6):832-6. PubMed ID: 12447939
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
